Celgene Corporation (CELG) Shares Sold by Patten Group Inc.

Patten Group Inc. reduced its stake in shares of Celgene Corporation (NASDAQ:CELG) by 1.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 18,522 shares of the biopharmaceutical company’s stock after selling 200 shares during the period. Patten Group Inc.’s holdings in Celgene Corporation were worth $1,861,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of the stock. First Financial Corp IN increased its position in shares of Celgene Corporation by 30.9% in the third quarter. First Financial Corp IN now owns 967 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 228 shares during the last quarter. Smithfield Trust Co. increased its position in shares of Celgene Corporation by 12.5% in the second quarter. Smithfield Trust Co. now owns 1,282 shares of the biopharmaceutical company’s stock valued at $127,000 after buying an additional 142 shares during the last quarter. Jolley Asset Management LLC increased its position in shares of Celgene Corporation by 2.1% in the third quarter. Jolley Asset Management LLC now owns 1,240 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 25 shares during the last quarter. Integrated Investment Consultants LLC increased its position in shares of Celgene Corporation by 2.2% in the third quarter. Integrated Investment Consultants LLC now owns 1,369 shares of the biopharmaceutical company’s stock valued at $138,000 after buying an additional 30 shares during the last quarter. Finally, Cornerstone Advisors Inc. increased its position in shares of Celgene Corporation by 202.8% in the third quarter. Cornerstone Advisors Inc. now owns 1,320 shares of the biopharmaceutical company’s stock valued at $138,000 after buying an additional 884 shares during the last quarter. 77.16% of the stock is owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Celgene Corporation (NASDAQ:CELG) opened at 115.61 on Friday. The company’s 50-day moving average is $116.15 and its 200 day moving average is $111.71. Celgene Corporation has a 52 week low of $94.39 and a 52 week high of $127.00. The stock has a market cap of $89.62 billion, a PE ratio of 46.43 and a beta of 1.74.

Celgene Corporation (NASDAQ:CELG) last announced its quarterly earnings results on Thursday, January 26th. The biopharmaceutical company reported $1.61 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.59 by $0.02. The firm had revenue of $2.98 billion for the quarter, compared to the consensus estimate of $3.03 billion. Celgene Corporation had a net margin of 17.80% and a return on equity of 77.95%. The business’s quarterly revenue was up 16.3% compared to the same quarter last year. During the same quarter last year, the firm posted $1.18 EPS. On average, analysts expect that Celgene Corporation will post $7.22 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Celgene Corporation (CELG) Shares Sold by Patten Group Inc.” was originally posted by sleekmoney and is the sole property of of sleekmoney. If you are viewing this report on another website, it was illegally copied and republished in violation of international trademark & copyright laws. The legal version of this report can be accessed at http://sleekmoney.com/celgene-corporation-celg-shares-sold-by-patten-group-inc/1656486.html.

CELG has been the subject of several analyst reports. Jefferies Group LLC reaffirmed a “buy” rating and set a $134.00 price target on shares of Celgene Corporation in a research note on Monday, October 17th. Canaccord Genuity set a $156.00 price target on shares of Celgene Corporation and gave the company a “buy” rating in a research note on Saturday, October 15th. Mizuho initiated coverage on shares of Celgene Corporation in a research note on Monday, November 7th. They set a “buy” rating and a $130.00 price target for the company. Zacks Investment Research raised shares of Celgene Corporation from a “hold” rating to a “buy” rating and set a $117.00 price target for the company in a research note on Wednesday, November 2nd. Finally, BTIG Research reaffirmed a “buy” rating and set a $138.00 price target on shares of Celgene Corporation in a research note on Monday, October 31st. One research analyst has rated the stock with a sell rating, four have issued a hold rating, twenty-four have issued a buy rating and one has given a strong buy rating to the stock. Celgene Corporation has a consensus rating of “Buy” and an average target price of $138.78.

About Celgene Corporation

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

5 Day Chart for NASDAQ:CELG

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/celgene-corporation-celg-shares-sold-by-patten-group-inc/1656486.html

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *